Read the latest news from our world of probiotics for dietary supplements and infant formula.
New partnership to develop treatment for peanut allergies
Prota Therapeutics, the developer of oral immunotherapies to treat food allergies, has partnered with Chr. Hansen. The partnership will assess the world’s best documented probiotic strain, LGG®, in a Phase III clinical trial to develop a treatment for peanut allergy.
New leader for Human Health will tap into attractive growth markets
With 25 years of experience in the consumer health care industry, Andrew Scorey joins Chr. Hansen as Senior Vice President, Human Health.
Chr. Hansen launches new online LGG® universe
The new online universe dedicated to the world’s best documented probiotic strain –Lactobacillus rhamnosus (LGG®) – provides scientific insights to why the LGG® strain is an excellent choice for dietary supplements, infant formula and fermented milk products.
Microbiome is our next generation of probiotics
New and exciting opportunities are emerging in this breakthrough area
100 new candidates for next generation probiotics
Translating groundbreaking science into new microbial solutions to improve health and prevent or treat disease
Seminar on probiotics for women's urogenital wellbeing
Did you know that some probiotics may support women’s urogenital wellbeing?
Study shows that probiotics may help pregnant women with GBS colonization
The study investigated the effect of Lactobacillus rhamnosus (GR-1®) and Lactobacillus reuteri (RC-14®) on pregnant women with Group B Streptococcus (GBS) colonization.
To further strengthen its probiotics offering Chr. Hansen acquires LGG®, the world’s best documented probiotic strain, from Valio OY
Natural solutions that advance human health are in high demand and the expected growth for microbial solutions in this industry is 7-9%. Chr. Hansen is the world’s leading supplier of probiotics to dietary supplements, infant formula and dairy, and through the acquisition of the LGG® business, the company is now further strengthening its microbial platform across all three categories.
Chr. Hansen presents new probiotics research at IPC 2016
At the upcoming IPC, 21-23 June 2016 in Budapest in Hungary, Senior Principal Scientist Thomas D. Leser at Human Health Discovery will be presenting a poster on some of our latest probiotics research.
See how our probiotic drops are made
Our probiotic drops are a convenient solution for infants and young children - safe, easy to dose and can be stored at room temperature (25°).
Our 3 USPs - it works, it lasts, it's different
Add value to your brand with Probio-Tec® probiotics.
Hear Eric Johansen talk about Bifidobacterium (BB-12®)
The BB-12® probiotic strain was introduced to the market in 1985. Today approx. 200 million people eat products, containing this particular probiotic strain. Eric Johansen is Associate Vice President, Science, at Chr. Hansen.
Chr. Hansen enters first collaboration on production of a next generation probiotic from the Human Microbiome
Today, Chr. Hansen and Caelus Health announce their collaboration on the development of Eubacterium hallii as a next generation probiotic for prevention and treatment of metabolic disease.
One of the world's largest clinical studies on probiotics reinforces significant gastrointestinal benefits of the probiotic strain named BB-12®
Millions of people around the world suffer from a range of gastrointestinal symptoms. Results from one of the world’s largest clinical studies on probiotics now show that the probiotic strain named BB-12® can be part of the solution by improving bowel regularity.
New study confirms presence of bifidobacteria and lactobacilli in breast milk from Chinese mothers
A study initiated by Chr. Hansen has shown that bifidobacteria and lactobacilli are present in breast milk from Chinese mothers, strengthening the case for adding clinically documented probiotics to infant formula, in order to improve nutrition.
Chr. Hansen accelerates efforts within human microbiome
Establishes a new research and development consortium and secures access and commercialization rights to an important resource of strains